Show simple item record

dc.contributor.authorStolz, Daiana
dc.contributor.authorPollak, Vincent
dc.contributor.authorChhajed, Prashant N.
dc.contributor.authorGysin, Christian
dc.contributor.authorPflimlin, Eric
dc.contributor.authorTamm, Michael
dc.date2022-08-11T08:09:32.000
dc.date.accessioned2022-08-23T16:34:39Z
dc.date.available2022-08-23T16:34:39Z
dc.date.issued2007-03-16
dc.date.submitted2009-03-16
dc.identifier.citationChest. 2007 Mar;131(3):765-72. <a href="http://dx.doi.org/10.1378/chest.06-2308">Link to article on publisher's site</a>
dc.identifier.issn0012-3692 (Print)
dc.identifier.doi10.1378/chest.06-2308
dc.identifier.pmid17356091
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38382
dc.description.abstractBACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17356091&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1378/chest.06-2308
dc.subjectAdministration, Inhalation
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAlbuterol
dc.subjectBronchodilator Agents
dc.subject*Bronchoscopy
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectForced Expiratory Volume
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPremedication
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectStatistics as Topic
dc.subjectVital Capacity
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleA randomized, placebo-controlled trial of bronchodilators for bronchoscopy in patients with COPD
dc.typeJournal Article
dc.source.journaltitleChest
dc.source.volume131
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1248
dc.identifier.contextkey782915
html.description.abstract<p>BACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy.</p>
dc.identifier.submissionpathoapubs/1248
dc.contributor.departmentDepartment of Pulmonary, Allergy and Critical Care Medicine
dc.source.pages765-72


This item appears in the following Collection(s)

Show simple item record